OpenNashEarnings

Pharmaceuticals · NYSE: JNJ

Johnson & Johnson earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends January · next results expected around 20 Jan 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 FY2026

Johnson & Johnson reported Q3 2026 sales growth of 5.9% to $25.4 Billion, with EPS of $0.09 (after a one-time special charge for the proposed talc litigation resolution) and adjusted EPS* of $2.59.

Johnson & Johnson's third-quarter sales rose 5.9% to $25.4 billion, driven by Innovative Medicine (up 7.7%) on TREMFYA, DARZALEX and CAPLYTA. MedTech grew only 2.5%, which management said fell short of its expectations. Reported EPS was $0.09 because of a charge for the proposed talc settlement and two deals, Firefly Bio and Sail Biomedicines. Adjusted EPS was $2.59, down 7.5%.

Read the Q3 FY2026 summary →Q3 FY2026 slides (PDF) ↗Official transcript (PDF) ↗

Quarters

KPI history

Revenue$25.4B+5.9% y/yQ3 FY26
Q4 FY24: $22.5B (worked out from the annual figure)Q4 24$22.5BQ1 FY25: $21.9BQ1 25$21.9BQ2 FY25: $23.7BQ2 25$23.7BQ3 FY25: $24.0BQ3 25$24.0BQ4 FY25: $24.6B (worked out from the annual figure)Q4 25$24.6BQ1 FY26: $24.1BQ1 26$24.1BQ2 FY26: $25.3BQ2 26$25.3BQ3 FY26: $25.4BQ3 26$25.4B

Fourth quarter worked out from the annual figure.

Data
Q4 FY24$22.5B *
Q1 FY25$21.9B
Q2 FY25$23.7B
Q3 FY25$24.0B
Q4 FY25$24.6B *
Q1 FY26$24.1B
Q2 FY26$25.3B
Q3 FY26$25.4B
Diluted EPS (GAAP)$0.09−95.8% y/yQ3 FY26
Q1 FY25: $4.54Q1 25$4.54Q2 FY25: $2.29Q2 25$2.29Q3 FY25: $2.12Q3 25$2.12Q1 FY26: $2.14Q1 26$2.14Q2 FY26: $2.27Q2 26$2.27Q3 FY26: $0.09Q3 26$0.09
Data
Q1 FY25$4.54
Q2 FY25$2.29
Q3 FY25$2.12
Q1 FY26$2.14
Q2 FY26$2.27
Q3 FY26$0.09

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Free cash flow$6.4B−20.6% y/yQ3 FY26
Q4 FY24: $5.4BQ4 24$5.4BQ1 FY25: $3.4BQ1 25$3.4BQ2 FY25: $2.8BQ2 25$2.8BQ3 FY25: $8.0BQ3 25$8.0BQ4 FY25: $5.5BQ4 25$5.5BQ1 FY26: $1.5BQ1 26$1.5BQ2 FY26: $7.3BQ2 26$7.3BQ3 FY26: $6.4BQ3 26$6.4B
Data
Q4 FY24$5.4B
Q1 FY25$3.4B
Q2 FY25$2.8B
Q3 FY25$8.0B
Q4 FY25$5.5B
Q1 FY26$1.5B
Q2 FY26$7.3B
Q3 FY26$6.4B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$22.5Bd$21.9B$23.7B$24.0B$24.6Bd$24.1B$25.3B$25.4B
Gross margin68.3%66.4%67.9%69.6%67.6%66.3%68.2%68.1%
Net income$3.4Bd$11.0B$5.5B$5.2B$5.1Bd$5.2B$5.5B$210.0M
Diluted EPS—$4.54$2.29$2.12—$2.14$2.27$0.09
Operating cash flow$7.0Bd$4.2B$3.9Bd$9.2Bd$7.3Bd$2.5B$8.6Bd$7.7Bd
Capital expenditure$1.6Bd$795.0M$1.0Bd$1.2Bd$1.8Bd$1.0B$1.3Bd$1.4Bd
Free cash flow$5.4B$3.4B$2.8B$8.0B$5.5B$1.5B$7.3B$6.4B
R&D expense$5.3Bd$3.2B$3.5B$3.7B$4.3Bd$3.5B$3.7B$4.7B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-Q and 10-K filings